• GeparSixto研究探讨了在蒽环、紫衫以及贝伐基础上,再加入卡铂,能否改善三阴性乳腺癌患者新辅助治疗的疗效;
  • 本研究旨在对上述临床试验的数据进行二次分析,探讨BRCA基因突变状态在其中扮演的角色;
  • 总计291名患者,BRCA基因突变率为17.2%;
  • 在未加入卡铂的患者中,BRCA基因突变患者的pCR率为66.7%,野生型为36.4%;
  • BRCA突变的患者,加入卡铂并未提高pCR:66.7% VS 65.4%;
  • BRCA未突变的患者,加入卡铂并提高pCR:55% VS 36.4%。
JAMA Oncology [IF:24.799]

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial



2017-07-13, Article

Abstract & Authors:展开

Importance: The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether BRCA1 and BRCA2 germline mutation status affects treatment outcome remains elusive.
Objective: To determine whether BRCA1 and BRCA2 germline mutation status affects therapy response in patients with TNBC.
Design, Setting, and Participants: This secondary analysis of a randomized clinical trial used archived DNA samples and cancer family history of 315 patients with TNBC enrolled between August 1, 2011, and December 31, 2012, in the GeparSixto trial. In all, 291 participants (92.4%) were included in this multicenter prospective investigation. DNA samples were analyzed for germline mutations in BRCA1, BRCA2, and 16 other cancer predisposition genes. The pCR rates between the carboplatin and noncarboplatin arms were compared. Genetic analyses were performed at the Center for Familial Breast and Ovarian Cancer in Cologne, Germany; data analysis, November 1 through December 31, 2015.
Main Outcomes and Measures: Proportion of patients who achieved pCR and disease-free survival after neoadjuvant treatment according to BRCA1 and BRCA2 germline mutation status. For pCR rates, the ypT0/is ypN0 definition was used as a primary end point.
Results: Of the 291 patients with TNBC, all were women; the mean (SD) age was 48 (11) years. The pCR rate in the carboplatin group was 56.8% (83 of 146) and 41.4% (60 of 145) in the noncarboplatin group (odds ratio [OR], 1.87; 95% CI, 1.17-2.97; P = .009). Pathogenic BRCA1 and BRCA2 germline mutations were present in 50 of the 291 patients (17.2%). In the noncarboplatin arm, the pCR rate was 66.7% (16 of 24) for patients with BRCA1 and BRCA2 mutations and 36.4% (44 of 121) for patients without (OR, 3.50; 95% CI, 1.39-8.84; P = .008). The high pCR rate observed in BRCA1 and BRCA2 mutation carriers (16 of 24 [66.7%]) was not increased further by adding carboplatin (17 of 26 [65.4%]). In contrast, carboplatin increased response rates in patients without BRCA1 and BRCA2 mutations: 66 of the 120 patients (55%) without BRCA1 and BRCA2 mutations achieved pCR in the carboplatin arm vs 44 of the 121 patients (36.4%) in the noncarboplatin arm (OR, 2.14; 95% CI, 1.28-3.58; P = .004). Patients without pathogenic BRCA1 and BRCA2 alterations showed elevated disease-free survival rates when carboplatin was added (without carboplatin, 73.5%; 95% CI, 64.1%-80.8% vs with carboplatin, 85.3%; 95% CI, 77.0%-90.8%; hazard ratio, 0.53; 95% CI, 0.29-0.96; P = .04).
Conclusions and Relevance: Under the nonstandard GeparSixto polychemotherapy regimen, patients without BRCA1 and BRCA2 germline mutations benefited from the addition of carboplatin and those with BRCA1 and BRCA2 mutations showed superior response rates without additive effects observed for carboplatin.
Trial Registration: Identifier: NCT01426880.

First Authors:
Eric Hahnen

Correspondence Authors:
Eric Hahnen

All Authors:
Eric Hahnen,Bianca Lederer,Jan Hauke,Sibylle Loibl,Sandra Kröber,Andreas Schneeweiss,Carsten Denkert,Peter A Fasching,Jens U Blohmer,Christian Jackisch,Stefan Paepke,Bernd Gerber,Sherko Kümmel,Christian Schem,Guido Neidhardt,Jens Huober,Kerstin Rhiem,Serban Costa,Janine Altmüller,Claus Hanusch,Holger Thiele,Volkmar Müller,Peter Nürnberg,Thomas Karn,Valentina Nekljudova,Michael Untch,Gunter von Minckwitz,Rita K Schmutzler